529POsimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study.

Autor:	Gillis, R1 (AUTHOR), Peled, N1 (AUTHOR), Goldshtien, I1 (AUTHOR), Rotem, O2 (AUTHOR), Rozenblum, A B2 (AUTHOR), Nechushtan, H3 (AUTHOR), Chen, L2 (AUTHOR), Dudnik, E2 (AUTHOR), Zer, A4 (AUTHOR), Yust-Katz, S2 (AUTHOR), Shelef, I5 (AUTHOR), Roisman, L C1 (AUTHOR), Inbar, E2 (AUTHOR)
Zdroj:	Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu